3-[4-[(2S,3R,4S,5S,6R)-4,5-二羟基-6-(羟基甲基)-3-[(2S,3R,4R,5R,6S)-3,4,5-三羟基-6-甲基-四氢吡喃-2-基]氧基-四氢吡喃-2-基]氧基苯基]-5,7-二羟基-苯并吡喃-4-酮 | 2945-88-2

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 异黄酮类化合物
• 中文名称: 3-[4-[(2S,3R,4S,5S,6R)-4,5-二羟基-6-(羟基甲基)-3-[(2S,3R,4R,5R,6S)-3,4,5-三羟基-6-甲基-四氢吡喃-2-基]氧基-四氢吡喃-2-基]氧基苯基]-5,7-二羟基-苯并吡喃-4-酮
• 中文别名: 槐属双苷
• 英文名称: Sophorabioside
• 英文别名: 3-[4-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxyphenyl]-5,7-dihydroxychromen-4-one
• CAS: 2945-88-2
• 化学式: C₂₇H₃₀O₁₄
• 分子量: 578.5
• InChiKey: SNJVNAXLTOIYQN-XQCQZFFBSA-N

物化性质

• 熔点：
  248° (slight decompn)
• 比旋光度：
  D19 -73° (0.27 g in 10 ml pyridine)
• 沸点：
  895.1±65.0 °C(Predicted)
• 密度：
  1.69±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  41
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  225
• 氢给体数：
  8
• 氢受体数：
  14

制备方法与用途

生物活性方面，Sophorabioside 是一种从紫花忍冬中分离出的黄酮苷。

文献信息

• Pharmaceutical composition containing substance inhibiting HSP47 production
  申请人：Kureha Chemical Industry Co., Ltd.

  公开号：EP0742012A2

  公开（公告）日：1996-11-13

  A pharmaceutical composition comprising a substance inhibiting HSP47 production, selected from the group consisting of a malt extract, a flavonoid compound, a protein-bound-polysaccharide obtained from a fungus belonging to Coriolus versicolor, a paeoniflorin derivative, a tocopherol derivative, and a ferulic acid derivative, and a pharmaceutically acceptable carrier is disclosed. The substance inhibiting HSP47 production can efficiently improve physiological conditions of a patient suffering from diseases exhibiting pathosis of overproduction of the extracellular matrix, and efficiently treat such diseases. Further, the substance is useful for preventing or treating various diseases accompanied with abnormal growth of the vascularization.

  本发明公开了一种药物组合物，该组合物包含一种抑制 HSP47 生成的物质，该物质选自麦芽提取物、黄酮类化合物、从属于 Coriolus versicolor 的真菌中获得的蛋白结合多糖、芍药苷衍生物、生育酚衍生物和阿魏酸衍生物组成的组，以及一种药学上可接受的载体。这种抑制 HSP47 生成的物质可以有效改善患有细胞外基质过度生成病症的患者的生理状况，并有效治疗此类疾病。此外，该物质还可用于预防或治疗伴有血管异常生长的各种疾病。
• [EN] COMPOUND SEPARATED FROM ROOT BARK OF GINKGO BILOBA AND USE THEREOF<br/>[FR] COMPOSÉ SÉPARÉ DE L'ÉCORCE DE RACINE DE GINKGO BILOBA ET SON UTILISATION<br/>[ZH] 一种银杏根皮中分离得到的化合物及其用途
  申请人：ZHEJIANG CONBA PHARM CO LTD

  公开号：WO2020199568A1

  公开（公告）日：2020-10-08

  一种银杏根皮中分离得到的化合物"银杏根皮酸"，即1,8-二羟基-二苯并呋喃-2,6-二羧酸，其分子式为C14H8O7，还公开了该化合物提取分离方法及其在银杏叶提取物中鉴定银杏根皮提取物的应用。
• Compounds exhibiting efflux inhibitor activity and composition and uses thereof
  申请人：Wempe Fitzpatrick Michael

  公开号：US20070254859A1

  公开（公告）日：2007-11-01

  At least one compound chosen from compounds of Formula I: a pharmaceutically acceptable salt or ester thereof, a solvate thereof, a chelate thereof, a non-covalent complex thereof, a prodrug thereof, and mixtures of any of the foregoing, wherein: n is a number from 1 to 900, wherein the individual units may be the same or different; W is chosen from alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, aralkyl and substituted aralkyl; each of R 2 , R 3 , R 4 and R 5 is independently chosen from —H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, aralkyl and substituted aralkyl; Z′ is chosen from —O—, —N—, —NO—, —NR 4 —, —S—, —SO— and —SO 2 —, wherein R 4 is defined as above; each of X, X′, Y and Z is independently chosen from —CR 4 R 5 —, —NH—, —NR 4 —, —NO—, —O—, —NOR 4 —, —S—, —SO—, —SO 2 —, wherein R 4 and R 5 are defined as above; R 1 is chosen from a tocopherol, a steroid and a flavonoid; and R 6 is chosen from any R 1 , alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, aralkyl and substituted aralkyl.
• PHARMACEUTICAL COMPOSITION CONTAINING SOPHORA JAPONICA L. EXTRACT AS ACTIVE INGREDIENT FOR THE PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISORDERS
  申请人：UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY

  公开号：US20190231835A1

  公开（公告）日：2019-08-01

  Provided is a pharmaceutical composition containing, as an active ingredient, a Sophora japonica L. extract, for the prevention and treatment of neurodegenerative disorders and improvement of cognitive functions. Particularly, it was confirmed that the Sophora japonica L. extract, according to the present invention, has a significant effect in an Alzheimer's Disease-causing mouse model, through a Y-maze test and a Morris water maze test, thereby confirming that the Sophora japonica L. extract could be useful as an active ingredient in the pharmaceutical composition for the prevention and treatment of neurodegenerative disorders and the improvement of cognitive functions.
• METHOD OF PREVENTING AND TREATING NEURODEGENERATIVE DISORDERS USING SOPHORA JAPONICA L. EXTRACT AS ACTIVE INGREDIENT
  申请人：UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY

  公开号：US20220080015A1

  公开（公告）日：2022-03-17

  Provided is a pharmaceutical composition containing, as an active ingredient, a Sophora japonica L . extract, for the prevention and treatment of neurodegenerative disorders and improvement of cognitive functions. Particularly, it was confirmed that the Sophora japonica L . extract, according to the present invention, has a significant effect in an Alzheimer's Disease-causing mouse model, through a Y-maze test and a Morris water maze test, thereby confirming that the Sophora japonica L . extract could be useful as an active ingredient in the pharmaceutical composition for the prevention and treatment of neurodegenerative disorders and the improvement of cognitive functions.